Who is sponsoring NCT06165874?

NCT06165874 is sponsored by Huashan Hospital.

What drugs are being tested in NCT06165874?

Interventions in NCT06165874: [68Ga]Ga-NOTA-RW102 PET Imaging.

What condition does NCT06165874 study?

NCT06165874 studies Non-small Cell Lung Cancer.

Is NCT06165874 still recruiting?

NCT06165874 is currently status unknown. Last updated 12 December 2023.

Last reviewed 2023-12-12 · How we verify

NCT06165874

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

[68Ga]Ga-NOTA-RW102 PET Imaging in the Diagnosis of PD-L1-expressing Lung Cancer

Status unknown NA Last updated 12 December 2023

What this trial tests

NA trial testing [68Ga]Ga-NOTA-RW102 PET Imaging in Non-small Cell Lung Cancer in 20 participants. Status unknown.

Timeline

12 March 2023

Primary endpoint
13 October 2023

14 January 2024

Quick facts

Lead sponsor	Huashan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	12 March 2023
Primary completion	13 October 2023
Estimated completion	14 January 2024
Sites	1 location across China

Drugs / interventions tested

[68Ga]Ga-NOTA-RW102 PET Imaging

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Huashan Hospital

Who can join

Adults 18 to 65, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to establish and optimize the imaging method of \[68Ga\]Ga-NOTA-RW102, as well as its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent was evaluated in patients with non-small cell lung cancer

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Preclinical development of novel PD-L1 tracers and first-in-human study of [<sup>68</sup>Ga]Ga-NOTA-RW102 in patients with lung cancers.
Zhang Y, Cao M, Wu Y, Malih S, et al · · 2024 · cited 23× · PMID 38580333 · DOI 10.1136/jitc-2024-008794
Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.
Zeven K, Lauwers Y, De Mey L, Debacker JM, et al · · 2024 · cited 8× · PMID 39281708 · DOI 10.1093/immadv/ltae006

Verify or expand the search:

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Huashan Hospital trials

Trials by the same sponsor.

NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06165874 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
Last refreshed: 12 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06165874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing